In addition to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2/neu (HER2/neu), a number of additional markers have been thoroughly investigated to determine their association with the clinicopathological features of breast cancer as well as their function in treatment selection and outcome modification. Here, ERBB2 is linked to breast carcinoma.